Ortho Regenerative Technologies, Inc. (OTCMKTS:ORTIF) is a medical technology company focused on the development, manufacturing and commercialization of innovative orthobiologic products that support bone healing and regeneration. Founded in 2012 and headquartered in Bridgewater, New Jersey, the company leverages proprietary processing techniques to supply surgeons with off-the-shelf allograft solutions. Through both internally developed products and strategic partnerships, Ortho Regenerative offers a growing portfolio intended for use in orthopedic, spine, trauma and dental procedures.
The company’s product suite includes cellular and acellular bone grafts, demineralized bone matrices and composite bone substitutes. Signature offerings such as ViviGen™ demographic tissue products and Trinity™ Evolution cellular bone allografts are designed to provide osteoconductive scaffolding, osteoinductive signaling and, in some cases, viable cells to support the biological processes of bone repair. Ortho Regenerative also markets molded and injectable bone void fillers under the Bio6™ and AlphaGRAFT™ brands, targeting applications ranging from fracture repair to degenerative spinal conditions.
Ortho Regenerative primarily serves the United States, collaborating with a network of independent distributors and directly with leading hospitals, surgery centers and private orthopedic practices. The company continues to explore international distribution agreements, with initial shipments underway in select European and Asia-Pacific markets. This geographic diversification is aimed at extending its regenerative technologies to a broader surgical community and expanding on its core strength in allograft processing and regulatory compliance.
Under the leadership of President and CEO Nancy S. Lowe, the executive team combines decades of experience in medical device development, supply chain management and clinical affairs. The board of directors includes seasoned professionals from orthopedics, biomanufacturing and healthcare investment, guiding Ortho Regenerative in its mission to deliver safe, effective and readily available bone repair solutions. As the field of regenerative medicine evolves, the company remains committed to advancing its scientific platform and broadening its product pipeline to address unmet needs in musculoskeletal care.
AI Generated. May Contain Errors.
Free ORTIF Stock Alerts